Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Published:2015-12-07 Issue:8 Volume:22 Page:1951-1957
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Tarlock Katherine,Alonzo Todd A.,Gerbing Robert B.,Raimondi Susana C.,Hirsch Betsy A.,Sung Lillian,Pollard Jessica A.,Aplenc Richard,Loken Michael R.,Gamis Alan S.,Meshinchi Soheil

Funder

Children's Oncology GroupAlex's Lemonade Stand Foundation Young Investigator

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndrome;Pediatric Blood & Cancer;2024-07-04

2. Navigating Treatment Options and Communication in Relapsed Pediatric AML;American Society of Clinical Oncology Educational Book;2024-06

3. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia;Blood Advances;2024-04-26

4. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations;Journal of Clinical Oncology;2024-04-01

5. De Novo AML;Pediatric Oncology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP